Product Images Ramipril

Table 3 shows the combined components and endpoints of the HOPE study, which evaluated the effects of placebo and Ramipril. The combined endpoint included myocardial infarction, stroke, or death from a cardiovascular cause. Ramipril showed a significant reduction in this endpoint compared to placebo. Component endpoints included death from cardiovascular causes, myocardial infarction, and stroke, with Ramipril showing a significant reduction in all three compared to placebo. Overall mortality was also reduced with Ramipril.*

The text is a description of a figure showing Kaplan-Meier estimates of the composite outcome of myocardial infarction, stroke, or death from cardiovascular causes in the Ramipril group and the placebo group. The figure displays a plot of the proportion of patients experiencing the outcome over time (in days) of follow-up. The x-axis shows 500, 1000, and 1500 days of follow-up, while the y-axis shows the proportion of patients. The plot shows that the Ramipril group had a lower proportion of patients experiencing the outcome compared to the placebo group. No additional information is available.*

The given text is a summary of Combined Endpoints and Components in Diabetics from the HOPE study. It provides data about the incidence of myocardial infarction, stroke, or death from cardiovascular causes in both Placebo and Ramipril groups. The study indicates a positive effect of Ramipril on lowering the risk of cardiovascular events in various subgroups like age, sex, hypertension, prior myocardial. The outcome shows a relative risk reduction of 25% with a P-value of 0.0004, and the beneficial effect of treatment with Ramipril is presented in a graph.*

This is a table showing the reasons for discontinuation or temporary interruption of treatment for a study called "HOPE." The study had two groups: one group received a placebo and the other group received ramipril. The table shows that 32% of the placebo group and 34% of the ramipril group discontinued treatment at any time. Of those who discontinued, 28% of the placebo group and 29% of the ramipril group permanently discontinued treatment. The table also shows the reasons for stopping, including cough, hypotension or dizziness, and angioedema with different percentages for both groups.*

This is a description of Ramipril Capsules, USP, with a strength of 2.5mg, manufactured by Aurobindo Pharma Limited in Hyderabad, India for BluePoint Laboratories. It includes dosage and administration instructions, a warning to keep the medication out of reach of children, and a note for pharmacists to dispense the capsules in a light-resistant container with a child-resistant closure. It is meant for prescription use only.*

Ramipril Capsules is a prescription drug containing 5mg of Ramipril USP, provided in a hard gelatin capsule. The product should be stored in a controlled room temperature ranging between 20°C to 25°C (68°F to 77°F), and dispensing should be in a light-resistant container with a child-resistant closure. BluePoint Laboratories is the distributor of this medication, which is manufactured by Aurobindo Pharma Limited in Hyderabad, India. The package insert should be read for dosage and administration information. Keep the medication out of reach of children. No information is available about the over printing zone coding area.*

This is a description of Ramipril capsules manufactured by Aurobindo Pharma Limited in Hyderabad, India for BluePoint Laboratories. The capsules contain 10 mg of Ramipril USP and are packaged in light-resistant, tight containers with child-resistant closures. The pharmacist is advised to read the package insert for prescribing information and to warn patients to keep the medication out of the reach of children. The capsules should be stored at 20° to 25°C (68° to 77°F). There is a warning printed in the text stating that the was unable to determine the exact legibility of the over printing zone coding area.*